Circulating tumor DNA predicts clinical benefits of immune checkpoint blockade in HER2-negative patients with advanced gastric cancer
Variation signatures captured by ctDNA as well as the kinetics of ctDNA could predict the clinical benefits of ICB in HER2-negative GC patients, which was worth further validated in large cohort.
Authors
- Congcong Ji
- Shiqing Chen (ORCID: https://orcid.org/0000-0002-7544-9916)
- Mei He
- Zhiwei Li (ORCID: https://orcid.org/0000-0002-9375-7138)
- Cheng Zhang (ORCID: https://orcid.org/0000-0002-1290-8855)
- Jing Gao (ORCID: https://orcid.org/0000-0002-3613-9413)
- Lin Shen (ORCID: https://orcid.org/0000-0003-1134-2922)
Institutions
- Peking University (CN)
- Peking University Cancer Hospital (CN)
- Peking University Shenzhen Hospital (CN)
- University of Hong Kong - Shenzhen Hospital (CN)
- Ministry of Education (ET)
Publication Details
- Journal
- Gastric Cancer
- Published
- 2025-05-15
- DOI
- https://doi.org/10.1007/s10120-025-01621-x
- Citations
- 4
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 3.75
Funders
- Beijing Xisike Clinical Oncology Research Foundation
- National Natural Science Foundation of China
- Peking University
- Peking University Third Hospital
- Beijing Nova Program
- Sanming Project of Medicine in Shenzhen
- Fundamental Research Funds for the Central Universities